Revolution Medicines, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for patients with RAS-addicted cancers, which represent approximately 30% of human cancers; its research and development pipeline centers on proprietary RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including the pan-RAS inhibitor daraxonrasib (RMC-6236), the RAS(ON) G12C-selective inhibitor elironrasib (RMC-6291), and the RAS(ON) G12D-selective inhibitor zoldonrasib (RMC-9805). These inhibitors target previously undruggable frontier targets in the RAS pathway and mTOR signaling through tri-complex mechanisms to enhance drug-target engagement and overcome resistance. The company operates primarily in the United States with global clinical development activities and serves patients and healthcare providers in oncology. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines leverages its RAS(ON) drug discovery platform to advance late-stage programs. In June 2025, the company entered a transformative $2 billion funding arrangement with Royalty Pharma, comprising up to $1.25 billion in synthetic royalty financing (with $250 million upfront) on daraxonrasib and up to $750 million in senior secured debt to support global development, Phase 3 trials in pancreatic cancer and non-small cell lung cancer, commercialization, and pipeline expansion; this partnership enables Revolution Medicines to retain full control over its programs while advancing multiple Phase 3 trial launches. Recent updates include progress on daraxonrasib's Phase 3 readiness and a technology collaboration with Iambic announced in November 2025 to further enhance its RAS inhibitor portfolio.
Company News
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLC
3,373 Shares of Revolution Medicines, Inc. $RVMD Bought by First Citizens Bank & Trust Co.
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines, Inc. $RVMD Stock Acquired by Assenagon Asset Management S.A.
Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Here Are Monday’s Top Wall Street Analyst Research Calls: Align Technology, AutoNation, Estee Lauder, Harley-Davidson, HubSpot, Microsoft, Mosaic, Ryder System, Wells Fargo & Company, and More
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Engineers Gate Manager LP Buys 4,356 Shares of Revolution Medicines, Inc. $RVMD
Stephen Michael Kelsey Sells 92,531 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Concurrent Investment Advisors LLC Invests $475,000 in Revolution Medicines, Inc. $RVMD
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer